Present status and future perspective of peptide-based vaccine therapy for urological cancer

Area of Science:

• Oncology
• Immunology
• Vaccinology

Background:

• Peptide-based vaccines are synthesized for cancer therapeutics to elicit immune responses via tumor antigen epitopes.
• These vaccines are generally safe and well-tolerated in vivo, with a history of progress in urological cancers over decades.
• Despite advancements, no peptide vaccine has received worldwide approval, though some show clinical efficacy and induce high immune responses.

Purpose of the Study:

• To review the mechanism of action for peptide-based vaccine therapy against tumors.
• To discuss the development of a specific peptide vaccine.
• To explore recent clinical trials and future perspectives for peptide-based vaccines in urological cancers, especially in combination with other therapies.

Main Methods:

• Review of existing literature on peptide-based vaccines and cancer immunotherapy.
• Discussion of preclinical and clinical data regarding peptide vaccine efficacy.
• Analysis of the role of immune checkpoint inhibitors in augmenting vaccine therapy.

Main Results:

• Peptide vaccines can induce significant immune responses and clinical efficacy in cancer patients.
• Combination therapy with immune checkpoint inhibitors shows potential for enhanced therapeutic outcomes.
• Ongoing research and clinical trials are exploring the full potential of peptide vaccines.

Conclusions:

• Peptide-based vaccines represent a viable therapeutic avenue for cancer, particularly urological malignancies.
• The integration of peptide vaccines with advanced immunotherapies like immune checkpoint inhibitors is a key area for future development.
• Further research and clinical validation are necessary to achieve worldwide approval and widespread clinical application.